VivoSim Labs to Showcase Multiparametric Human 3D Tissue Safety Data at the American College of Toxicology (ACT) 47th Annual Meeting
Key Highlights
- ➤VivoSim to present multiparametric 3D human tissue safety data at ACT 47th Annual Meeting
- ➤Data spans multi-compound benchmarks, small molecules, and antibody-drug conjugates
- ➤Platform targets clinically predictive DILI and gastrointestinal toxicity risk stratification
- ➤Executive and scientific teams to discuss platform integration and commercial partnerships
Expert Statements
Amar Sethi, Chief Scientific Officer of VivoSim Labs
“We look forward to sharing our latest translational methodology with the global toxicological community at ACT”
SAN DIEGO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a leader in next-generation New Approach Methodologies (NAMs) 3d human cellular models for preclinical safety and translational efficacy, today announced that its scientific team will present new translational safety data at the American College of Toxicology (ACT) 47th Annual Meeting, November 15–18, 2026 in San Antonio, Texas.
The presentations will feature data generated across large multi-compound benchmarks and emerging modalities, including small molecules and antibody-drug conjugates (ADCs), demonstrating how VivoSim’s 3D human primary tissue platforms inform clinical safety risk for customer compounds under non-animal testing frameworks. The data will highlight that VivoSim’s multiparametric approach, measuring multiple tissue outcomes rather than overt cell death alone, provides a more detailed picture and superior predictive power.
Get started
Create a free account to read the full story.